Market News

Supernus Pharmaceuticals, Inc. (SUPN) Reaches $38.53 After 8.00% Up Move; B2W COMPANHIA GLOBAL DO VAREJO ORDINARY (BZWHF) Shorts Down By 83.12%

The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) is a huge mover today! The stock increased 3.45% or $1.2843 during the last trading session, reaching $38.5343. About 154,121 shares traded. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has risen 91.80% since February 21, 2017 and is uptrending. It has outperformed by 75.10% the S&P500.The move comes after 6 months positive chart setup for the $1.98 billion company. It was reported on Feb, 21 by We have $41.62 PT which if reached, will make NASDAQ:SUPN worth $158.00M more.

B2W COMPANHIA GLOBAL DO VAREJO ORDINARY (OTCMKTS:BZWHF) had a decrease of 83.12% in short interest. BZWHF’s SI was 3,900 shares in February as released by FINRA. Its down 83.12% from 23,100 shares previously. The stock increased 72.66% or $2.77233 during the last trading session, reaching $6.5877. About 950 shares traded or Infinity% up from the average. B2W CIA DIGITAL (OTCMKTS:BZWHF) has 0.00% since February 21, 2017 and is . It has underperformed by 16.70% the S&P500.

Since September 7, 2017, it had 0 buys, and 10 insider sales for $15.31 million activity. Shares for $249,303 were sold by Bhatt Padmanabh P. on Friday, September 8. Schwabe Stefan K.F. had sold 95,000 shares worth $4.43M. 24,250 shares valued at $1.12M were sold by Vaughn Victor on Wednesday, January 17. PATRICK GREGORY S also sold $2.18 million worth of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) on Thursday, January 11.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. The company has market cap of $1.98 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. It has a 35.06 P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

Among 11 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Supernus Pharmaceuticals has $66 highest and $27 lowest target. $47.64’s average target is 23.63% above currents $38.5343 stock price. Supernus Pharmaceuticals had 36 analyst reports since August 26, 2015 according to SRatingsIntel. On Monday, November 6 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) earned “Hold” rating by Piper Jaffray on Thursday, August 3. The rating was maintained by Jefferies with “Buy” on Thursday, August 3. As per Monday, July 18, the company rating was downgraded by Northland Capital. The company was maintained on Wednesday, November 8 by B. Riley & Co. Cowen & Co maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating on Monday, October 23. Cowen & Co has “Buy” rating and $50.0 target. The stock has “Buy” rating by Cowen & Co on Tuesday, September 19. The firm has “Buy” rating given on Friday, October 6 by Jefferies. The company was maintained on Friday, September 1 by Stifel Nicolaus. The stock has “Hold” rating by Stifel Nicolaus on Tuesday, September 19.

Analysts await Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) to report earnings on February, 27 after the close. They expect $0.26 earnings per share, 0.00% or $0.00 from last year’s $0.26 per share. SUPN’s profit will be $13.33 million for 37.05 P/E if the $0.26 EPS becomes a reality. After $0.29 actual earnings per share reported by Supernus Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -10.34% negative EPS growth.

Investors sentiment decreased to 0.98 in Q3 2017. Its down 0.34, from 1.32 in 2017Q2. It fall, as 22 investors sold Supernus Pharmaceuticals, Inc. shares while 97 reduced holdings. 42 funds opened positions while 75 raised stakes. 48.75 million shares or 3.64% more from 47.04 million shares in 2017Q2 were reported. Avalon Advisors Llc holds 32,632 shares or 0.04% of its portfolio. Sei Investments Company reported 248,193 shares stake. Aqr Mgmt Ltd Llc owns 87,629 shares or 0% of their US portfolio. Balyasny Asset Mngmt Limited Liability Corp invested in 145,625 shares. California Pub Employees Retirement System stated it has 47,090 shares or 0% of all its holdings. Swiss Bank & Trust accumulated 0% or 83,500 shares. Invesco Ltd owns 2.06 million shares or 0.03% of their US portfolio. Fmr Limited Liability Company invested in 0% or 65,900 shares. Loring Wolcott Coolidge Fiduciary Limited Liability Partnership Ma reported 34 shares stake. California State Teachers Retirement System invested 0.01% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Rosenblum Silverman Sutton S F Ca invested 0.11% of its portfolio in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Northpointe Capital Ltd Liability, a Michigan-based fund reported 251,526 shares. Envestnet Asset Inc has invested 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Lazard Asset Management Lc holds 0% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) or 53,650 shares. Smith Asset Mngmt Grp Ltd Partnership holds 61,367 shares or 0.08% of its portfolio.

Leave a Reply

Your email address will not be published. Required fields are marked *